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Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
syndrome is a maternally inherited mitochondrial disorder that is most commonly caused
by the m. 3243A>G mutation in the MT-TL1 mitochondrial DNA gene, resulting in
impairment of mitochondrial energy metabolism. Although childhood is the typical age
of onset, a small fraction (1–6%) of individuals manifest the disease after 40 years of age
and usually have a less aggressive disease course. The clinical manifestations are variable
and mainly depend on the degree of heteroplasmy in the patient’s tissues and organs.
They include muscle weakness, diabetes, lactic acidemia, gastrointestinal disturbances,
and stroke-like episodes, which are the most commonly observed symptom. We
describe the case of a 50-year-old male patient who presented with relapsing intestinal
pseudo-obstruction (IPO) episodes, which led to a late diagnosis of MELAS. After
diagnosis, he presented several stroke-like episodes in a short time period and developed
a rapidly progressive cognitive decline, which unfortunately resulted in his death. We
describe the variable clinical manifestations of MELAS syndrome in this atypical and
relatively old patient, with a focus on paralytic ileus and stroke-like episodes; the first
symptom may have driven the others, leading to a relentless decline. Moreover, we
provide a brief revision of previous reports of IPO occurrence in MELAS patients with
the m.3243A>G mutation, and we investigate its relationship with stroke-like episodes.
Our findings underscore the importance of recognizing gastrointestinal disturbance to
prevent neurological comorbidities.
Keywords: MELAS, mitochondrial disorders, intestinal pseudo-obstruction, stroke-like episodes, gastrointestinal
disturbance
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INTRODUCTION
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes (MELAS) syndrome is one of the most common
maternally inherited mitochondrial disorders, with an estimated
prevalence of 0.2:100,000 in Japan (1). MELAS was first described
by Pavlakis in 1984 (2). The most common genetic defect
is an adenine to guanine transition at position 3243 on the
mitochondrial DNA in the MT-TL1 gene, which encodes the
transfer RNA (tRNA)Leu(UUR). The prevalence of this mutation
was found to be higher than previously reported, with a
prevalence of 0.24% in a large Caucasian population (236 out of
100000 persons) (3). The m.3243A>Gmutation results in altered
mitochondrial translation and protein synthesis, which affect the
electron transport chain (ETC) complex subunit structure and
lead to impaired mitochondrial energy production (4).
Defects in mitochondrial metabolism lead to a disparity
between dysfunction in energy generation and energy demand
from organs and tissue. Therefore, the signs and symptoms are
extremely variable and mostly involve organs with higher energy
requirements that are particularly vulnerable to an insufficient
energy supply, such as the nervous system and the skeletal
and cardiac muscles. Nevertheless, given the heteroplasmy
phenomenon (i.e., different tissues and organs harbor different
amounts of mutant mtDNA, since the mutation is not present in
all copies of the mtDNA, and the mutant mtDNA is randomly
distributed among daughter cells during cell division), clinical
manifestations are variable among different individuals and
among different tissues in the same patient.
Stroke-like episodes are paradigmatic symptoms of MELAS.
These symptoms occur in almost all affected individuals and
represent a common initial clinical manifestation. They manifest
with an acute onset neurological deficit that is sometimes
accompanied by headache, vomiting, and seizures. Other
common signs and symptoms of the disease are represented by
muscle weakness, exercise intolerance, diabetes, lactic acidemia,
dementia, and gastrointestinal disturbances.
Intestinal pseudo-obstruction (IPO) is most commonly
observed in mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE), although this symptom can
also affect patients with MELAS syndrome (5), particularly
those with the m.3243A>G mutation; however, IPO remains
an underrecognized condition. IPO is a rare and severe
condition that is characterized by abdominal distension, nausea,
vomiting, and pain due to impaired propulsive activity in
the gastrointestinal tract and resembles mechanical intestinal
obstruction (6). The pathophysiological mechanisms underlying
IPO in mitochondrial disorders are most likely related to
mitochondrial dysfunction and energy metabolism imbalance,
similar to the situation in the brain during stroke-like episodes.
The importance of this condition has been identified recently,
since it can represent a prognostic factor in m.3243A>Gmutated
patients (7).
We describe the case of a 50-year-old male patient who
started to develop ideomotor decline and relapsing episodes
of abdominal distension, pain, and vomiting after an ischemic
stroke, which were consistent with a diagnosis of IPO.
Brain magnetic resonance imaging (MRI), magnetic resonance
spectroscopy (MRS), muscle biopsy and genetic analysis led
us to reconsider the previous ischemic stroke as a stroke-like
episode and revealed a late diagnosis ofMELAS syndrome caused
by the m.3243A>G mutation. After diagnosis, several stroke-
like episodes occurred in a short time period, leading to a
rapidly progressive cognitive decline and finally to the patient’s
death.
Although the adult form of MELAS syndrome is thought
to display a more favorable course, our patient exhibited an
aggressive and rapidly progressing deterioration. Gastrointestinal
disturbance and stroke-like episodes share common pathogenic
mechanisms (i.e., dysfunction in mitochondrial energy
production); one symptom may precipitate the other, triggering
a cascade of stroke-like episodes and leading to metabolic failure
in the patient. Given the late clinical presentation, presence
of gastrointestinal dysmotility and peculiar clinical course,
our patient can provide interesting insights into both the
pathophysiology and management of mitochondrial diseases. In
particular, earlier detection of gastroenterological disturbances in
these patients may prompt earlier identification of neurological
comorbidities, leading to appropriate therapeutic strategies and
improved clinical outcomes.
CASE REPORT
A 50-year-old man received medical attention due to subacute
onset of relapsing intestinal subocclusion episodes characterized
by vomiting, diarrhea and marked abdominal distension, which
gradually developed within approximately 40 days.
His past medical history included dyslipidemia and previous
lipoma removal; additionally, his relatives reported apathy, loss
of interest in work and hobbies and progressive social isolation
occurring over the last two years. Two months before his
presentation, he was hospitalized for acute onset of blurred vision
and phosphenes in the left visual field that were associated with
a frontal headache and confusion. The neurological evaluation
revealed left hemianopia, temporal, and spatial disorientation
and moderate psychic and motion slowness. Brain computed
tomography (CT) and MRI showed a right temporo-occipital
lesion with a high signal in the diffusion-weighted imaging
(DWI) sequences, which was interpreted as an ischemic stroke
(Figure 1A). The intracranial vessels were normal at the
CT angiogram (CTA). The clinical course was complicated
by a focal epileptic seizure with subsequent generalization;
therefore, an antiepileptic therapy with carbamazepine was
started.
To investigate the causes of intestinal obstruction, several
diagnostic assessments were conducted. He underwent an
abdominal CT and MRI and a colonoscopy to rule out expansive
and infiltrative lesions, and total body positron emission
tomography (PET) and a periumbilical fat biopsy were performed
to exclude systemic vasculitis and amyloidosis, respectively.
Therefore, a diagnosis of chronic intestinal pseudo-obstruction
(IPO) was formulated. The patient was treated with pro-kinetic
drugs and supported with parenteral nutrition, with progressive
clinical improvement and restoration of intestinal transit. Lab
tests also showed high serum lactate (1.7 mmol/l, normal range
0.0–1.3 mmol/l), hyponatremia and hypokalemia, probably due
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FIGURE 1 | Temporal evolution of brain magnetic resonance imaging (MRI). FLAIR (fluid attenuated recovery) sequences are shown in the upper line, and DWI
(diffusion-weighted imaging) sequences are shown in the lower line. (A) First stroke-like episode initially interpreted as an ischemic stroke. A high signal occurred in the
diffusion-weighted imaging (DWI) sequences in the right temporo-occipital lobes and the corresponding fluid attenuated recovery (FLAIR) sequence. (B) Second
stroke-like episode: three months later, evidence of a wider lesion was found in the right temporal, parietal and occipital lobes together with initial enlargement of the
ventricular spaces. (C) Third stroke-like episode: a new cortical DWI abnormality was observed in the left medial temporal and occipital lobes; marked and diffuse
atrophy was found in the brain parenchyma.
to inappropriate secretion of antidiuretic hormone syndrome
(SIADH) caused by the carbamazepine therapy. The electrolytic
disturbance was corrected, and carbamazepine was replaced with
levetiracetam without neurological clinical improvement.
Hewas admitted to ourNeurologyDepartment for persistence
of confusion and development of left arm clumsiness and
stiffness. The brain MRI was repeated and showed evolution
of the right hemispheric lesion, which extended to the parietal
lobe and the anterior and medial parts of the temporal lobe and
involved the subcortical white matter and cortex (Figures 1B,
2A,B). The electroencephalogram (EEG) showed slow persistent
activity and periodic lateralized epileptiform discharges (PLEDs)
in the right hemisphere, whereas the brain PET revealed
a severe reduction in cortical glucose metabolism in the
posterior right hemisphere (Figure 2C). Therefore, a metabolic
etiology of the disturbance was suspected. To confirm this
hypothesis, the patient underwent MR spectroscopy (MRS) and
demonstrated elevation of the lactate peak within the abnormal
lesion (Figure 2D), a muscle biopsy that was consistent with
mitochondrial myopathy (Figures 2E–H) and genetic testing,
which revealed the presence of a mitochondrial DNA mutation
(m.3243A>G) (heteroplasmy 13.1%) in the MT-TL1 gene
encoding the leucine transfer RNA. A diagnosis of MELAS was
formulated, and therapy with oral arginine, ubidecarenone and
riboflavin was administered to the patient.
The genetic analysis was extended to his sister, nephews
and two first grade cousins; the family tree is shown
in Supplementary Figure 1. Four of these family members
were positive for heteroplasmy and were asymptomatic. The
audiological examination revealed bilateral sensorineural hearing
loss.
Three months after hospital discharge, the patient presented
with a new onset of an acute confusional state, visual illusion
in the right visual field and severe frontal headache. At the
neurological examination, the patient appeared confused, slowed
down and disoriented. The confrontation visual field test showed
right superior quadrantopsia together with the previous left
hemianopsia. He also had face-blindness, visual agnosia, left
upper arm apraxia and mild anomic aphasia. The lab tests
showed increased serum lactate (2.9 mmol/l; normal range 0.0–
1.3 mmol/l). A partial resolution of the previous right cortical
lesion and the presence of a new cortical DWI abnormality
in the left medial temporal and occipital lobes was observed
at the brain MRI (Figure 1C, lower part), revealing a new
stroke-like episode. Additionally, the Fluid Attenuated Recovery
(FLAIR) sequences identified a marked and greater cortical
atrophy with increased ventricular sizes (Figure 1C, upper part).
To counter the vasogenic edema resulting from blood-brain
barrier dysfunction due to mitochondrial microangiopathy, the
patient received intramuscular corticosteroids (dexamethasone
8mg), but the treatment was prematurely stopped due to onset of
drug-induced diabetes mellitus, and insulin therapy was started.
In the following month, the patient developed a rapidly
progressive ideomotor decline; the patient had spatial and
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FIGURE 2 | Diagnostic assessment of MELAS syndrome. (A–B) Cortical diffusion-weighted imaging abnormalities in the right temporal, parietal and occipital lobes
with corresponding fluid attenuated inversion recovery hyperintensity. (C) Brain positron emission tomography (PET) revealed a severe reduction in cortical glucose
metabolism in the posterior right hemisphere. (D) MR spectroscopy (MRS) showed elevation of the lactate peak within the abnormal lesion. (E–H) Muscle biopsies. (E)
Modified Gomori Trichrome stain (40X) showing a typical Ragged Red muscle fiber (RRF) containing mitochondrial hyperproliferation. (F) Succinate dehydrogenase
(SDH) stain (40X) confirming mitochondrial hyperproliferation in the same fiber. (G) Cytochrome C oxidase (COX) stain (40X) demonstrating muscle cells with
decreased mitochondrial activity. (H) COX/SDH combo reaction (20X) showing diffuse fibers with COX deficiency and SDH positivity scattered in the muscle.
temporal disorientation, psychomotor agitation, speech
disturbance with confabulation and cortical-blindness. A
new left lateral temporal and occipital lesion was identified
on brain MRI (not available); oral arginine therapy was
increased, and intravenous L-arginine was administered.
During hospitalization, the patient suffered again from acute
IPO and was treated conservatively. He also manifested a
non-convulsive epileptic status. To achieve seizure control,
lacosamide, phenytoin, and clobazam were progressively added
to the levetiracetam. Despite therapeutic implementation, the
patient did not recover, and he died one month later (Figure 3).
DISCUSSION
We describe a late-onset MELAS syndrome case due to the
classic m.3243A>G mutation that presented with relapsing IPO
episodes. The patient suffered from several stroke-like episodes
in rapid sequence, which contributed to a rapid and relentless
ideomotor deterioration and carried him to a fatal ending.
Some elements make this patient atypical. Firstly, he presented
for medical attention at the age of 50 years and was almost
completely asymptomatic until the first stroke-like episode
occurred. Childhood represents the typical age of onset of
MELAS patients, with onset occurring before or at 20 years of
age in 65–76% of cases (8). Only a few cases (1–6%) are older
than 40 years of age at presentation. Second, he presented a
particularly aggressive clinical course and died only a fewmonths
after onset of the disease. In contrast, usually the juvenile form is
associated with a more aggressive course and deterioration than
the adult form (1), and juvenile patients commonly have faster
disease progression and higher mortality than adults (1). This
disease course probably depends on two aspects: the cells of the
organism need higher amounts of energy during childhood due
to system development, and an early presentation of symptoms is
more often associated with a higher mutation load in the mtDNA
(9). Despite the high percentage of relatives carrying the disease-
causative mutation, our patient is the only affected member of
his family to date. This result could be partially due to the
heteroplasmy phenomenon and the younger ages of his relatives,
who may present later in time; nevertheless, other mechanisms
may be involved in determining the clinical presentation.
One of the main clinical features of our patient was the
occurrence of relapsing IPO episodes concomitant with his
first clinical presentation. Although it is mainly reported in
association with MNGIE, a paralytic ileus can also represent
a severe complication in MELAS-affected patients and seems
to be relatively frequent in patients harboring the m.3243A>G
mutation (10). Furthermore, gastrointestinal involvement is
more severe in MELAS patients with the m.3243A>G mutation
than in MNGIE patients (11). Chronic IPO with any cause
affects 0.9 out of 100000 people (12), whereas the minimum
prevalence of IPO in patients with the m.3243A>G mutation
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FIGURE 3 | Timeline representing the clinical disease course. Major clinical episodes are shown in the first line, and the diagnostic assessments performed and
treatments are reported in the second and third lines, respectively. IPO, intestinal pseudo-obstruction; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes; PLED, period lateralized epileptiform discharges.
is 0.53 per 100000 (11). Sekino et al. found a 40% prevalence
of IPO in MELAS-affected patients and reported a lower age
at onset and at diagnosis in patients with IPO than in those
without IPO in their cohort (13). In a large observational study
of 215 patients harboring the m.3243A>G mutation, 13% of the
patients presented acutely with IPO (11).
The pathophysiological mechanisms underlying
gastrointestinal dysmotility in mitochondrial disorders are
not completely understood and most likely involve myenteric
plexus neuropathy and visceral myopathy. The identification
of cytochrome c oxidase (COX) deficiency within the smooth
muscle layers of the gastrointestinal tract in two patients carrying
the classic mutation in the MT-TL1 gene supports the evidence
of visceral myopathy in mitochondrial patients (14). Moreover,
numerous and enlarged mitochondria in smooth muscle cells
and the cytoplasm of ganglion cells were found in a segment
of resected ileum and colon from a MELAS-affected patient
(5). These findings suggest that mitochondrial dysfunction
and energy production impairment may be the basis for the
gastrointestinal symptoms in these patients, similar to the effects
in the brain during stroke-like episodes.
Stroke-like episodes manifest with an acute onset neurological
deficit that is sometimes accompanied by headache, vomiting
and seizures. Since gastrointestinal disturbance and stroke-like
episodes share common cellular and molecular substrates, their
concomitant occurrence is not unlikely.
We conducted a comprehensive literature search of the
MEDLINE database from 2000 to September 2018 and retrieved
11 studies and case reports describing the occurrence of
IPO in MELAS syndrome patients (Table 1). The terms used
for the search were as follows: (MELAS OR mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes OR
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TABLE 1 | Case reports of intestinal pseudo-obstruction in MELAS syndrome.
Reference author,
date
IPO after MELAS
diagnosis
Concomitant IPO
and MELAS
diagnosis
GI involvement
before MELAS
diagnosis
IPO treatment and outcome Other comments
Sekino et al. (13) 6 2 1 Conservative 2 deceased from
cardiomyopathy, 1 deceased from
cerebral infarction, 1 deceased from
epilepsy and aspiration pneumonia
–
Ng et al. (11) – 8 1 3 surgery
4 deceased from aspiration pneumonia
8 concomitant IPO and
stroke-like
Suzuki (15) 3 – 2 Conservative
Died from aspiration pneumonia
–
Betts et al. (14) 2 – 1 Conservative –
Primiano et al. (16) – – 1 Prucalopride
Recovery
–
Chang et al. (5) 1 – 1 Laparoscopy MELAS/MNGIE overlap
Chiyonobu (17) 1 – – Conservative Concomitant IPO and status
epilepticus
Nakae (18) 1 – – Conservative
Recovery
Concomitant IPO and status
epilepticus
Seessle (19) 1 – – Subtotal colectomy, ileorectostomy
Recovery
–
García-Velasco et al.
(20)
1 – 1 Conservative
Recovery
Concomitant IPO and
stroke-like
Muehlenberg et al.
(21)
– 1 1 Gastrectomy for perforation
Survival
Concomitant diagnosis and
stomach perforation
IPO, intestinal pseudo-obstruction; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Sixteen cases presented with IPO occurring after the MELAS
diagnosis, concomitant IPO and MELAS diagnosis were reported in 11 patients (see Comments for specimens; e.g., concomitant IPO and stroke-like episode), and general gastro-
enteric symptoms were reported before the MELAS diagnosis in nine patients. Conservative treatments consisted of laxative agents, antidiarrheal drugs, antiflatulence agents,
mosapride, dimethicone, pantothenic acid, daikenchuto (Chinese herbal medicine), neostigmine or distigmine, domperidone, mosapride citrate, butyric acid bacteria, sodium picosulfate,
prostaglandin F2 alpha, pantothenic acid, dioctyl sodium sulfosuccinate or eritromycine.
mitochondrial diseases) AND (intestinal pseudo obstruction OR
gastrointestinal involvement).
Garcia-Velasco and colleagues described the case of a newly
diagnosed patient who presented with simultaneous stroke-like
and IPO symptoms (20). In a recent observational study aimed
at determining the prevalence of IPO in m.3243A>G-related
mitochondrial disease manifesting with IPO, 8 of 30 patients
developed a stroke-like episode simultaneously with IPO (11).
In the same cohort, relapsing IPO episodes preceded the first
stroke-like episodes by approximately 20 years (11). To the best
of our knowledge, gastrointestinal symptoms, especially IPO,
led to the diagnosis of MELAS in six patients (11, 13, 21). We
summarized the previous reports of MELAS syndrome patients
with the occurrence of IPO in Table 1.
In our case, the occurrence of IPO led us to reconsider
the previous ischemic stroke diagnosis as a stroke-like episode
and to postulate a diagnosis of MELAS. Additionally, the brain
MRI performed during acute presentation of IPO showed an
evolution of the previously observed lesion. Since that time,
several stroke-like episodes had occurred over a short time
period, as if the first stroke-like episode had triggered a cascade of
events and led to progressive, rapid, and unstoppable multiorgan
metabolic failure. Furthermore, the patient experienced a rapidly
progressive cognitive decline, which carried him to death, as if
the disease had assumed a neurodegenerative trend until reaching
a point of no return. Finally, our patient was almost completely
asymptomatic until the age of 50 years, when the first stroke-like
episode occurred.
In the case described here, the manifestation of IPO
developed over a period of time that was almost concomitant
with the appearance of the first stroke-like episode. Precisely
determining that one of the two symptoms was the precipitating
cause of the other is difficult. The gastrointestinal dysfunction
accompanied the progressive deterioration from the first
episode to the final worsening that led to the exitus. We
speculated that the energy balance of cells of our patient,
even if unstable, remained well-compensated for a long
time until a single event (e.g., the first stroke-like episode
or the acute IPO) overcame a threshold and induced the
breakdown of the energetic system, prompting multiorgan
deterioration. Indeed, he developed a severe ideomotor decline
that was entirely comparable to a neurodegenerative process;
he had a focal epileptic status, manifested diabetes and
suffered from chronic relapsing IPO. The gastrointestinal
disturbance could have played a determinant role in this frail
scenario as both a causative agent and an epiphenomenon
of a fatal disease. A centrally mediated mechanism called
the “neurogastrointestinal crisis” has also been hypothesized
to explain the concomitant occurrence of severe stroke-like
episodes and IPO (11).
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Recently, the prognostic role of IPO in mitochondrial
disorders has been recognized, in particular in patients carrying
the m.3243A>G mutation (7). Indeed, IPO is most frequently
observed in patients with multiorgan involvement and a higher
disease burden (11).
However, together with positive urine heteroplasmy,
a low mass body index (BMI) and a history of
cardiomyopathy, stroke-like episodes represent the
strongest predictor for developing IPO (Hazard Ratio 2.93,
p= 0.01) (11).
Treatment of stroke-like episodes includes intravenous
L-arginine in the acute phase and oral L-arginine, riboflavin,
and idebenone (coenzyme Q is able to cross the blood brain
barrier) in the interictal phases (22). High-dose intravenous
corticosteroids have been used to reduce the vasogenic
edema of stroke-like lesions (23, 24). Management of the
paralytic ileus should be based on conservative treatment,
since surgical intervention has been associated with a
poor prognosis in patients with mitochondrial diseases.
In particular, a successful outcome has been obtained
with prucalopride (16). Unfortunately, medical therapy
was ineffective in our patient due to the elevated disease
burden.
In conclusion, IPO as a manifestation of mitochondriopathy
is a misdiagnosed and underdiagnosed entity. Additionally,
a longstanding history of gastrointestinal dysmotility is often
underestimated before acute presentation. Since stroke-like
episodes and intestinal dysmotility can interfere with each other
and may predict a worse clinical outcome, clinicians should be
aware of the possibility of an even worse prognosis.
Early detection of chronic gastroenterological disturbances in
mitochondriopathies may prompt precocious identification of
neurological comorbidities, leading to appropriate therapeutic
strategies and improved clinical outcomes.
ETHICS STATEMENT
The case report has been performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments. Informed written consent
was obtained from the participant for the publication of this
manuscript.
AUTHOR CONTRIBUTIONS
All authors took care of patient management and made decisions
about patient treatment. DG and EM conceived the idea, revised
the literature, and wrote the manuscript. FM, DV, and MM
performed a critical revision of the manuscript for important
intellectual content. EA, RB, and IF acquired the clinical data.
DP and DR performed the genetic analysis. FT analyzed and
interpreted the brain imaging. LP and MS analyzed the muscle
biopsy. RB, EM, FM, and AG collected the clinical data and
contributed to manuscript preparation. NB, GC, SC, and AG
contributed to manuscript revision and read and approved the
submitted version.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fneur.
2019.00038/full#supplementary-material
Supplementary Figure 1 | Patient’s family pedigree showing transmission of
3243A>G through four generations.
REFERENCES
1. Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T,
et al. MELAS: a nationwide prospective cohort study of 96 patients in Japan.
Biochim Biophys Acta (2012) 1820:619–24. doi: 10.1016/j.bbagen.2011.03.015
2. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP.
Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike
episodes: a distinctive clinical syndrome. Ann Neurol. (1984) 16:481–8.
doi: 10.1002/ana.410160409
3. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P,
et al. Population prevalence of the MELAS A3243G mutation.Mitochondrion
(2007) 7:230–3. doi: 10.1016/j.mito.2006.12.004
4. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical
manifestations, pathogenesis, and treatment options.Mol GenetMetab. (2015)
116:4–12. doi: 10.1016/j.ymgme.2015.06.004
5. Chang T-M, Chi C-S, Tsai C-R, Lee H-F, Li M-C. Paralytic ileus in
MELAS with phenotypic features of MNGIE. Pediatr Neurol. (2004) 31:374–7.
doi: 10.1016/j.pediatrneurol.2004.05.009
6. Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer
AD. Pathophysiology, diagnosis, and management of chronic
intestinal pseudo-obstruction. J Clin Gastroenterol. (2018) 52:477–89.
doi: 10.1097/MCG.0000000000001047
7. Suzuki J, Iwata M, Moriyoshi H, Nishida S, Yasuda T, Ito Y. Gastro-
intestinal involvement in m.3243A>G-associated mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like episodes. Intern Med. (2018)
57:771. doi: 10.2169/internalmedicine.9632-17
8. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy,
lactic acidosis, and strokelike episodes (MELAS): current concepts.
J. Child Neurol. (1994) 9:4–13. doi: 10.1177/0883073894009
00102
9. Tuppen HAL, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA
mutations and human disease. Biochim Biophys Acta (2010) 1797:113–28.
doi: 10.1016/j.bbabio.2009.09.005
10. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of
mitochondrial neurogastrointestinal encephalomyopathy. Brain (2011)
134:3326–32. doi: 10.1093/brain/awr245
11. Ng YS, Feeney C, Schaefer AM, Holmes CE, Hynd P, Alston CL.
et al. Pseudo-obstruction, stroke, and mitochondrial dysfunction: a
lethal combination. Ann Neurol. (2016) 80:686–92. doi: 10.1002/ana.
24736
12. Iida H, Ohkubo H, Inamori M, Nakajima A, Sato H. Epidemiology and
clinical experience of chronic intestinal pseudo-obstruction in Japan:
a nationwide epidemiologic survey. J Epidemiol. (2013) 23:288–94.
doi: 10.2188/jea.JE20120173
13. Sekino Y, Inamori M, Yamada E, Ohkubo H, Sakai E, Higurashi
T, et al. Characteristics of intestinal pseudo-obstruction in patients
with mitochondrial diseases. World J Gastroenterol. (2012) 18:4557–62.
doi: 10.3748/wjg.v18.i33.4557
14. Betts J, Barron MJ, Needham SJ, Schaefer AM, Taylor RW,
Turnbull DM. Gastrointestinal tract involvement associated with the
3243A>G mitochondrial DNA mutation. Neurology (2008) 70:1290–2.
doi: 10.1212/01.wnl.0000308940.38092.74
Frontiers in Neurology | www.frontiersin.org 7 January 2019 | Volume 10 | Article 38
Gagliardi et al. Relevance of IPO in MELAS
15. Suzuki J, IwataM,Moriyoshi H, Nishida S, Yasuda T, Ito Y. Familial pernicious
chronic intestinal pseudo-obstruction with a mitochondrial dna a3243g
mutation. Int Med. (2017) 56:1089–93. doi: 10.2169/internalmedicine.56.7753
16. Primiano G, Plantone D, Forte F, Sauchelli D, Scaldaferri F, Gasbarrini A,
et al. Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of
prucalopride. Neurology (2014) 82:1932–4. doi: 10.1212/WNL.00000000000
00458
17. Chiyonobu T, Noda R, Yoshida M, Fujiki A, Ishii R, Nukina S,
et al. Intestinal pseudo-obstruction in a patient with mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS) associated with phenytoin therapy. Brain Dev. (2008) 30:430–3.
doi: 10.1016/j.braindev.2007.12.006
18. Nakae Y, Kishida H, Hakii Y, Koyano S, Suzuki Y, Kuroiwa Y. Distigmine
bromide improves chronic intestinal pseudo-obstruction in a case of MELAS.
Rinsho Shinkeigaku (2007) 47:177–9.
19. Seessle J, Stremmel W, Ebinger F, Merle U. An unusual case of
paralytic ileus. Z Gastroenterol. (2012) 50:1161–5. doi: 10.1055/s-0032-13
13125
20. García-Velasco A, Gómez-Escalonilla C, Guerra-Vales JM, Cabello A, Campos
Y, Arenas J. Intestinal pseudo-obstruction and urinary retention: cardinal
features of a mitochondrial DNA-related disease. J Intern Med. (2003)
253:381–5. doi: 10.1046/j.1365-2796.2003.01095.x
21. Muehlenberg K, Fiedler A, Schaumann I, Müller-Felber W,
Wiedmann KH. [Intestinal pseudoobstructions and gastric necrosis in
mitochondrial myopathy]. Dtsch Med Wochenschr. (2002) 127:611–5.
doi: 10.1055/s-2002-22669
22. Koenig MK, Emrick L, Karaa A, Korson M, Scaglia F, Parikh S, et al.
Recommendations for the management of strokelike episodes in patients with
mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes.
JAMA Neurol. (2016) 73:591–4. doi: 10.1001/jamaneurol.2015.5072
23. Walcott BP, Edlow BL, Xia Z, Kahle KT, Nahed BV, Schmahmann JD. Steroid
responsive A3243G mutation MELAS: clinical and radiographic evidence for
regional hyperperfusion leading to neuronal loss. Neurologist (2012) 18:159–
70. doi: 10.1097/NRL.0b013e318247bcd8
24. Fryer RH, Bain J, De Vivo D. Mitochondrial encephalomyopathy
lactic acidosis and stroke-like episodes: a case report and critical
reappraisal of treatment options. Pediatr Neurol. (2016) 56:59–61.
doi: 10.1016/j.pediatrneurol.2015.12.010
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Gagliardi, Mauri, Magri, Velardo, Meneri, Abati, Brusa,
Faravelli, Piga, Ronchi, Triulzi, Peverelli, Sciacco, Bresolin, Comi, Corti and
Govoni. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s)
and the copyright owner(s) are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neurology | www.frontiersin.org 8 January 2019 | Volume 10 | Article 38
